TB Vaccine Linked to Better Type 1 Diabetes Control
A little more than three years after getting two tuberculosis shots four weeks apart, about 50 people with type 1 diabetes saw their long-term average blood sugar levels drop significantly -- and for at least five years. (Source: WebMD Health)
Source: WebMD Health - June 21, 2018 Category: Consumer Health News Source Type: news
TB Vaccine Tied to Better Type 1 Diabetes Control
A little more than three years after getting two tuberculosis shots four weeks apart, about 50 people with type 1 diabetes saw their long-term average blood sugar levels drop significantly -- and for at least five years. (Source: WebMD Health)
Source: WebMD Health - June 21, 2018 Category: Consumer Health News Source Type: news
Diabetes Breakthrough: Common Vaccine Can Improve Blood Sugar Levels Long-Term
BOSTON (CBS) – Researchers at Mass General Hospital announced a breakthrough in treating Type 1 Diabetes. In a long-term study released Thursday, patients in a clinical trial had their blood sugar levels restored to near normal, with lasting results.
Patients in the trial received two doses of the bacillus Calmette-Guerin (BCG) vaccine, an inexpensive vaccine that is widely used to prevent tuberculosis. Results were not immediate, but after three years, every patient, “showed an improvement in HbA1c to near normal levels – improvement that persisted for the following five years,” MGH said in a news release.
“This...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 21, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Diabetes Mass General Hospital Source Type: news
Study finds generic drug can reverse type 1 diabetes long-term
Research at Massachusetts General Hospital looks increasing like a long-term cure for type 1 diabetes, with a newly released study on Thursday showing patients have normal blood sugar levels eight years after a clinical trial.
In research published Thursday in journal npj Vaccines, patients who had been treated with the bacillus Calmette-Guerin (BCG) vaccine — an inexpensive, generic vaccine used around the world to prevent tuberculosis — had normal blood sugar levels eight years after the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 21, 2018 Category: American Health Authors: Jessica Bartlett Source Type: news
Researcher closes in on drug to reverse Type I diabetes
Research at Massachusetts General Hospital looks increasingly like a long-term cure for type 1 diabetes, with a newly released study showing patients have normal blood sugar levels eight years after a clinical trial.
In research published Thursday in journal npj Vaccines, patients who had been treated with the bacillus Calmette-Guerin (BCG) vaccine — an inexpensive, generic vaccine used around the world to prevent tuberculosis — had normal blood sugar levels eight years after the trial ended.… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 21, 2018 Category: American Health Authors: Jessica Bartlett Source Type: news
Are the BCG jabs a solution to type 1 diabetes? Patients' blood sugars drop to near-normal levels
Researchers from the Massachusetts General Hospital found that the BCG vaccines may increase glucose uptake by cells, which causes patient's blood-sugar levels to decrease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2018 Category: Consumer Health News Source Type: news
TB Vaccine Linked to Better Type 1 Diabetes Control
THURSDAY, June 21, 2018 -- Could a vaccine from the early 1900s be the key to preventing serious diabetes complications? Maybe, say researchers from Harvard University and Massachusetts General Hospital.
A little more than three years after getting... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 21, 2018 Category: General Medicine Source Type: news
MGH study finds generic drug can reverse Type I diabetes long-term
Research at Massachusetts General Hospital looks increasing like a long-term cure for type 1 diabetes, with a newly released study on Thursday showing patients have normal blood sugar levels eight years after a clinical trial.
In research published Thursday in journal npj Vaccines, patients who had been treated with the bacillus Calmette-Guerin (BCG) vaccine — an inexpensive, generic vaccine used around the world to prevent tuberculosis — had normal blood sugar levels eight years after the… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 21, 2018 Category: Health Management Authors: Jessica Bartlett Source Type: news
Speeding up the search for tuberculosis vaccines
An EU-funded project aims to identify and maximise the potential of novel vaccines to end the global tuberculosis epidemic. These could save lives, stem the spread of infection and shorten treatment for the often deadly, airborne disease. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - June 21, 2018 Category: Research Source Type: news
Cost and scale of field trials for bovine TB vaccine may make them unfeasible
(University of Cambridge) Field trials for a vaccination to protect cattle against bovine tuberculosis (bovine TB) would need to involve 500 herds -- potentially as many as 75,000-100,000 cattle -- to demonstrate cost effectiveness for farmers, concludes a study published today in the journal eLife. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 7, 2018 Category: Infectious Diseases Source Type: news
How intestinal worms hinder tuberculosis vaccination
(PLOS) New research in mice suggests that chronic infection with intestinal worms indirectly reduces the number of cells in lymph nodes near the skin, inhibiting the immune system's response to the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis. Xiaogang Feng of Karolinska Institutet in Stockholm, Sweden, and colleagues present these findings in PLOS Pathogens. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 17, 2018 Category: Infectious Diseases Source Type: news
Publication details IDRI's promising leprosy vaccine candidate
(Infectious Disease Research Institute) A publication in Nature Partner Journals (npj) Vaccines indicates that post-exposure prophylaxis with LepVax, IDRI's leprosy vaccine candidate, not only appears safe but, unlike BCG (a tuberculosis vaccine that provides some protection against leprosy), alleviates and delays the neurologic disruptions caused by Mycobacterium leprae infection in nine-banded armadillos. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 26, 2018 Category: Infectious Diseases Source Type: news
TB vaccine trial results offer potential for BCG Revaccination, hope for subunit vaccines
(Burness) Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. In a prevention-of-infection Phase 2 trial conducted in South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents. An experimental vaccine candidate, H4:IC31, also reduced sustained infections, although not at statistically significant levels. (Source: EurekAlert! - Infectio...
Source: EurekAlert! - Infectious and Emerging Diseases - February 19, 2018 Category: Infectious Diseases Source Type: news
Inovio lands $4.6M in funding for malaria, tuberculosis vaccines
Inovio Pharmaceuticals Inc. said Monday it has received $4.6 million in grant funding from the Bill& Melinda Gates Foundation and the National Institutes of Health to advance work on vaccine programs targeting tuberculosis and malaria.
The Plymouth Meeting biopharmaceutical company is conducting its research as part of its partnership with the Wistar Institute of Philadelphia.
Both programs involve the use of Inovio's SynCon synthetic vaccine technology that helps a person's own immune system… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 12, 2018 Category: Pharmaceuticals Authors: John George Source Type: news
